2012 Speakers Include

Who Should attend?
In attendance from the small molecule manufacturing sector are Site Leaders, Technical Leaders, Technical Services, General Managers, CEO’s & Managing Directors, and Suppliers. From the bio and drug development sector; R&D, Licensing, M&A, Finance and Business Development, Heads of Strategic Alliances, Market Analysts, Heads of Life Science, Policy Makers, Regulators, Academia and Legal and Financial Advisors will be attend.

John Kiernan, Vice President & Managing Director, Quintiles Ireland Limited.

John Kiernan has worked in the Pharmaceutical industry for over 30 years.  After graduating with an honours degree in Business, majoring in Marketing, he began his career in the pharmaceutical industry with Schering-Plough. He subsequently worked for Ovelle pharmaceuticals in a  variety of commercial roles rising ultimately to sit on the board of Ovelle as  Marketing Director.
In 1997 he established the commercial division of Quintiles in Ireland and held the role of General Manager of this division until 2003 when he was appointed Managing Director of Quintiles Ireland Limited.
In 2009 he was appointed to Vice-President & Managing Director Quintiles Ireland Limited & Commercial Solutions, Nordics

Dr Liam Tully, Director, Pfizer Global Process Development CentreDr. Liam Tully, Director, Pfizer Global Process Development Centre

Post a PhD in Organic Chemistry from Trinity College Dublin Liam has had a varied career in the Chemical industry working both in Agrochemicals and Pharma. He has worked in the SME sector and in a number of large multinational Pharma and currently is Director of Pfizer’s global Process Development Centre (PDC) based in Cork.  The PDC was established in 2002 to redesign API processes to increase competiveness.  Liam is a strong advocate of structured innovation and related inquiry systems and he himself was the recipient of the inaugural Pfizer global manufacturing ‘Innovator of the Year’ award. A holder of numerous patents and an international IChemE award, Liam and his team challenge competiveness on a daily basis using Innovation as their core competency.

Dr. Ambrose McLoughlin, Secretary General of the Department of Health

Dr. Ambrose McLoughlin BDS, MBA was appointed Secretary General of the Department of Health on 17th April 2012.

He holds the following qualifications:

Masters in Business Administration from University College Cork – Business School (1986);
Certificate in Public Administration – IPA (1979);
BDS, NUI – Dublin Dental School (1974).

He has over 30 years’ successful experience in the Health Service from Practitioner Level to Chief Executive. He was previously:
Registrar/Chief Executive of the Pharmaceutical Society of Ireland (PSI), the pharmacy regulator;
CEO North Eastern Health Board (NEHB);
Deputy CEO NEHB, responsible for Acute Hospitals and Community Services.

Frank Hallinan PhD, Biopharmaceutical Quality Consultant.

An experienced, creative biopharmaceutical leader with particular expertise in Biopharmaceutical Quality & Regulatory Affairs and biotechnology. Has led teams through significant changes and major start ups in Pfizer/Wyeth Biotech with an excellent compliance record, Irish Medicines Board and Schering Plough. As Quality Site Head managed an annual budget of over €40m, led a technical team of close to 400 people and pioneered and drove a business transformation program in latter years. Is an effective and persuasive communicator and teacher who can explain complex issues clearly and succinctly. Insider knowledge of the EU pharmaceutical regulatory systems and the QP role; adjunct professor of Pharmaceutical Regulatory Affairs in TCD and external examiner to the MSc program for training QPs at UCC, Ireland. Pro-active, creative and energetic in many work areas as evidenced by contributions to many professional and technical endeavours. Equally adept in public and private sector work environments.

Professor David Brayden, UCD

Professor David Brayden is Associate Professor of Drug Delivery at the School of Veterinary Medicine, University College Dublin (UCD) and a Fellow of the UCD Conway Institute. Following a Ph.D. in Pharmacology at the University of Cambridge, UK (1989), and a post-doctoral research fellowship at Stanford University, he set up Elan Corporation’s in vitro pharmacology laboratory in Dublin (1991). At Elan, he became a senior scientist and project manager of several of Joint-Venture drug delivery research collaborations with US biotech companies. At UCD since 2001, he became Director of the Science Foundation Ireland Research Cluster (The Irish Drug Delivery Network), specializing in oral and pulmonary delivery of biotech molecules (2007-2012). He is the author or co-author of more than 150 research publications and patents. Professor Brayden serves on the Editorial Advisory Boards of Drug Discovery Today and Advanced Drug Delivery Reviews and is an Associate Editor of Therapeutic Delivery. He was a co-founder and Chairman of the UK-Ireland Chapter of the Controlled Release Society (CRS) and served on the CRS Board of Scientific Advisors (2006-2009). He was the first Irish person to be made a member of the College of Fellows of the CRS in 2012.  Professor Brayden works as an independent consultant for several biotech companies.

Pat O’Mahony, Chief Executive, Irish Medicines Board

Mr. Pat O’Mahony, M.V.B., M.V.M., A.M.D., M.B.A., M.R.C.V.S., is Chief Executive of the Irish Medicines Board.
Having spent a number of years in private practice and as technical manager in the pharmaceutical industry in Ireland and the UK, he worked in public health and was Director of Consumer Protection at the Food Safety Authority of Ireland.
Mr. O’Mahony is a member of the Management Board of the European Medicines Agency where he served as Chairman from 2007 to 2011. He is also a member of the Board of the Food Safety Authority of Ireland, the Irish National Accreditation Board and a member of the National Patient Safety Advisory Group.

Mr. Jon O’Halloran   B.Sc MBA, Manager, Solid State Pharmaceutical Cluster (SSPC)

Jon is the Manager for the Solid State Pharmaceutical Cluster (SSPC), a research collaboration of 5 Universities and 9 Irish based Pharmaceutical Companies. An Industrial chemistry and MBA graduate from the University of Limerick; Jon has 20 years’ experience in the Pharmaceutical Industry and has worked from a number of multinational companies. His areas of industrial expertise are in new product introduction and validation, Active Pharmaceutical Ingredient (API) manufacturing and business development management. He has held a number of senior management positions in industry and has significant experience in managing projects as diverse as New Chemical Entity (NCE) introduction to manufacturing facilities in Ireland, transfer of marketing activities from Switzerland to Ireland and establishment of a Pharmaceutical Manufacturing base for a US corporation in Ireland. For the past 5 years Jon has managed the SSPC from a commercial perspective with particular emphasis on strategy development and delivery of industrial impact from the centre. A keen student of industrial:academic alliances Jon’s interest lies in the areas of capability based strategy development and knowledge management.

Professor Ian Marison, Director, NIBRT

Professor Marison is the Interim Director of NIBRT. He is also Professor of Bioprocess Engineering, Head of School of Biotechnology and Director of the Integrated Bioprocessing Laboratory (LiB) at Dublin City University.

His research group comprises 4 Post-doctoral researchers, 10 Postgraduate students, technical staff and administrative staff.

In addition, Professor Marison heads 19 Professors/ Lecturers and over 200 research and technical staff. His current research funding is €2.1 million. The research activities of Prof. Marison are broadly described by the term “integrated bioprocessing” and include:

• Integrated bioprocessing.

• High cell density cultures through process optimisation and on-line monitoring and control systems (microbial and animal cell cultures) and in-situ product recovery.

• Process analytical technologies (PAT: FIA, FTIR, dielectric spectroscopy, biocalorimetry, on-line mass and energy balancing, chemometrics).

• In-situ product recovery (ISPR; filtration, liquid-liquid extraction, perstraction, transmembrane distillation).

• Cell retention systems for perfusion (spin filters, inclined settlers etc.).

• Micro- and nano-encapsulation  (>5×107 cell/ml).

• Biocatalysis (enzyme, whole cell).

• High throughput screening.

• Non-parenteral drug delivery.

Dr. Ena Prosser, Partner, Fountain Healthcare Partners

Dr Ena Prosser is a Partner in Fountain Healthcare Partners. Ena was part of the team that raised Fountain Healthcare Partners Fund 1 in 2008. Ena is a PhD Immunologist by training and she has a broad background in international alliance and intellectual property management. She has led rigorous due diligence projects on technologies and products within the Specialty Pharma, diagnostic, device and biotechnology areas.

Ena was formerly Director of Enterprise Ireland BIO. In this role, she led a large team to identify, fund, protect and exploit relevant Intellectual Property, commercialise lifescience technologies and review investment opportunities in R&D.

Prior to Enterprise Ireland, Ena held various R&D and project management roles within Elan Corporation and had extensive involvement in drug delivery development, licensing and acquisition projects over a 9-year period. Ena has a strong innovation policy background and is a member of the Irish Government Innovation Taskforce in Intellectual Property, as well as being a council member of the Irish BioIndustry Association. She led the investments and is a board member of Genable Ltd, and Trino Therapeutics Ltd. Ena works closely with Ireland’s leading ophthalmology research charity Fighting Blindness. Ena is an Adjunct Professor at University College Dublin and she is a member of the Institute of Directors (Cert. Comp Dir).

Barry O’Leary CEO, IDA Ireland

Barry was appointed Chief Executive Designate of IDA Ireland in October 2007. He took over the role of CEO from Sean Dorgan on January 1st 2008. Prior to this appointment he was Divisional Manager of the IDA’s LifeSciences and Information and Communications Technology business units. Barry has worked in IDA for over 30 years in most of its business areas including two periods, 1983-1991 and 1995-2002 in Germany, latterly as Director of Europe.

On his return to Germany in 1995 he was responsible for running IDA’s offices in Stuttgart and Düsseldorf which covered Germany, Austria, Switzerland and Italy. He subsequently became Director of Europe and centralised IDA’s German offices into Frankfurt. During this period he was closely associated with winning major projects from companies such as Bertelsmann, SAP, Deutsche Bank, Lufthansa, Kostal, Allianz and a number of key Italian financial services Institutions.

On his return to Ireland in late 2002 Mr. O’Leary was initially appointed Divisional Manager Pharmaceuticals and Biopharmaceuticals and a member of the IDA’s Executive Committee. His responsibilities were increased in 2004 to include the LifeSciences and Information and Communications Technology areas.

He has been deeply involved in changing the profile and raising the value of Ireland’s inward investments over the past ten years, focusing on building capability in strategic sectors such as lifesciences and information and communications technology.

Barry led IDA teams in winning significant investments from a number of key clients such as Lilly, Pfizer, Centocor, Boston Scientific, Cordis, IBM, Kelloggs, Merck, Citi, Cisco Systems and Facebook among others.

Under his leadership in 2010, IDA launched its strategy blueprint, Horizon 2020. The strategy document articulates how IDA will attract the next wave of sophisticated FDI over the coming decade. It highlights the importance of global mega-trends, economic geopolitical changes and technology roadmaps which will influence where IDA can capitalise on the opportunities that they present.

Barry held a number of different positions in industrial companies prior to joining IDA Ireland, including Nestle and the Smurfit Group. He is a Board Member of Forfas.

Dr. Sally-Ann Cryan, Senior Lecturer in Pharmaceutics, RCSI

Sally-Ann Cryan graduated with a BSc. (Pharmacy) from Trinity College, Dublin (TCD) and subsequently carried out PhD research in the area of gene therapy in the Department of Pharmaceutics in TCD. After completing her PhD she went on to work as a Post-doctoral Research Fellow in the Royal College of Surgeons in Ireland. In 2003, she was awarded a Fulbright Scholarship to carry out research into novel gene and protein-based therapies for Cystic Fibrosis (CF) at the School of Pharmacy and School of Medicine, University of North Carolina at Chapel Hill (UNC-Chapel Hill). In 2004 she was appointed as Lecturer in Pharmaceutics in the School of Pharmacy, RCSI and was appointed to Senior Lecturer in Pharmaceutics in October 2008.

Prof. Cormac Taylor, UCD Conway Institute

Professor Cormac Taylor’s current research programme in molecular medicine is directed towards developing an innovative intestinal model of drug uptake and an enhanced drug delivery system. The programme, which works in association with Sigmoid Biotechnologies, is focused on the areas of infection, immunity and inflammation. The simulation model predicts accurately how efficiently a drug is absorbed into a patient’s bloodstream.
The research team under Professor Taylor recently discovered a potential treatment for Inflammatory Bowel Disease (IBD), which affects millions of people globally and more than 15,000 people in Ireland. Using a new class of drugs known as hydroxylase inhibitors, the research team demonstrated that they can almost completely reverse the symptoms of IBD in a model.

The findings have resulted in a cross-university partnership with the University of Colorado in Denver who are working on a different hydroxylase inhibitor in conjunction with UCD Conway Institute team’s industry partner, Sigmoid Biotechnologies. Their work will generate strong lead compounds for future clinical trials.

The Irish and US research groups will now begin a collaborative investigation to bring the discovery to the next stage which involves developing a new therapeutic treatment which can be delivered safely to patients. Professor Taylor has also led a collaborative research project with researchers based at the University of Dundee into the cellular responses to hypoxia.

Dr. Ruth Freeman, Director, Enterprise & International Affairs Science Foundation Ireland

Ruth was appointed as Director of Enterprise and International Affairs at Science Foundation Ireland (SFI) at the beginning of 2010, where her remit includes developing and fostering relationships with foreign agencies and forging strategic alliances in research and development.  She also interacts with companies and industry associations directly, as well as being the main SFI contact point with Enterprise Ireland and IDA Ireland. The Technology and Innovation Development Award at SFI is run under Dr Freeman’s direction.

Prior to her current appointment Dr Freeman was Head of Industry-Research Development at SFI with responsibility for coordinating all SFI award programmes involving industrial collaborations, including the Centres for Science, Engineering and Technology (CSET), Strategic Research Clusters (SRC) and Principal Investigator Industry Supplement programmes.   Ruth joined SFI as a Scientific Programme Manager in November 2006.

She has conducted research within several groups in Europe and Africa and has presented her research at many international conferences.  She has lectured on a variety of topics to M.Sc. and undergraduate students as well as assisting in the supervision of numerous undergraduate and postgraduate research projects.  Her PhD research, on population genetics in hybrid zones, was funded by a Studentship in Biodiversity from the Wellcome Trust and was carried out at TCD and ILRI, Nairobi. During this time she also obtained a Postgraduate Diploma in Statistics.

Ruth was also a founding member of the Trinity Research Staff Association; the first Irish association representing contract researchers.

John O’Dea, Manager, High Potential Start up Unit, Enterprise Ireland

John O’Dea is an engineer by background and is manager in the High Potential Startup and Scaling Division of Enterprise Ireland, with responsibility for early-stage Lfesciences, Engineering and Electronics sectors. Enterprise Ireland is the state agency that assists indigenous industry to grow and supports commercially-focused academic research.